ID   NQO2_HUMAN              Reviewed;         231 AA.
AC   P16083; B2R492; Q5TD04;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 5.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Ribosyldihydronicotinamide dehydrogenase [quinone];
DE            EC=1.10.5.1 {ECO:0000269|PubMed:18579530};
DE   AltName: Full=NRH dehydrogenase [quinone] 2;
DE   AltName: Full=NRH:quinone oxidoreductase 2;
DE   AltName: Full=Quinone reductase 2;
DE            Short=QR2;
GN   Name=NQO2; Synonyms=NMOR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-47.
RC   TISSUE=Liver;
RX   PubMed=1691923; DOI=10.1021/bi00459a034;
RA   Jaiswal A.K., Burnett P., Adesnik M., McBride O.W.;
RT   "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2)
RT   corresponding to a second member of the NAD(P)H:quinone oxidoreductase
RT   gene family. Extensive polymorphism at the NQO2 gene locus on
RT   chromosome 6.";
RL   Biochemistry 29:1899-1906(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-47.
RC   TISSUE=Liver;
RX   PubMed=8182056;
RA   Jaiswal A.K.;
RT   "Human NAD(P)H:quinone oxidoreductase 2. Gene structure, activity, and
RT   tissue-specific expression.";
RL   J. Biol. Chem. 269:14502-14508(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-47.
RA   Iida A., Osawa S., Kitamura Y., Kitamoto T., Koyama K., Nakamura Y.;
RT   "Human NRH:quinone oxidoreductase 2, complete genomic sequence.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16; GLY-29;
RP   PHE-47; ASP-58 AND ALA-184.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PHE-47.
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PHE-47.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PHE-47.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   CHARACTERIZATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9367528; DOI=10.1006/abbi.1997.0344;
RA   Wu K., Knox R., Sun X.Z., Joseph P., Jaiswal A.K., Zhang D.,
RA   Deng P.S.-K., Chen S.;
RT   "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a
RT   dihydronicotinamide riboside dependent oxidoreductase.";
RL   Arch. Biochem. Biophys. 347:221-228(1997).
RN   [10]
RP   CHARACTERIZATION.
RX   PubMed=9050836; DOI=10.1073/pnas.94.5.1669;
RA   Zhao Q., Yang X.L., Holtzclaw W.D., Talalay P.;
RT   "Unexpected genetic and structural relationships of a long-forgotten
RT   flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase).";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1669-1674(1997).
RN   [11]
RP   ERRATUM.
RA   Zhao Q., Yang X.L., Holtzclaw W.D., Talalay P.;
RL   Proc. Natl. Acad. Sci. U.S.A. 94:5979-5979(1997).
RN   [12]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15078100; DOI=10.1021/bi035923w;
RA   Kwiek J.J., Haystead T.A.J., Rudolph J.;
RT   "Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by
RT   the antimalarial quinolines.";
RL   Biochemistry 43:4538-4547(2004).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-80 AND SER-197, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=10433694; DOI=10.1021/bi990799v;
RA   Foster C.E., Bianchet M.A., Talalay P., Zhao Q., Amzel L.M.;
RT   "Crystal structure of human quinone reductase type 2, a
RT   metalloflavoprotein.";
RL   Biochemistry 38:9881-9886(1999).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) IN COMPLEX WITH RESVERATROL.
RX   PubMed=15350128; DOI=10.1021/bi049162o;
RA   Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T.-C., Wu J.M.,
RA   Zhang Z.;
RT   "Crystal structure of quinone reductase 2 in complex with
RT   resveratrol.";
RL   Biochemistry 43:11417-11426(2004).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) IN COMPLEX WITH CB1954, AND
RP   MUTAGENESIS OF ASN-162.
RX   PubMed=16129418; DOI=10.1016/j.bbrc.2005.08.081;
RA   Fu Y., Buryanovskyy L., Zhang Z.;
RT   "Crystal structure of quinone reductase 2 in complex with cancer
RT   prodrug CB1954.";
RL   Biochem. Biophys. Res. Commun. 336:332-338(2005).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH MELATONIN AND
RP   FAD, FUNCTION, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=18254726; DOI=10.1042/BJ20071373;
RA   Calamini B., Santarsiero B.D., Boutin J.A., Mesecar A.D.;
RT   "Kinetic, thermodynamic and X-ray structural insights into the
RT   interaction of melatonin and analogues with quinone reductase 2.";
RL   Biochem. J. 413:81-91(2008).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEXES WITH DOPAMINE AND
RP   ADRENOCHROME, AND ENZYME ACTIVITY.
RX   PubMed=18579530; DOI=10.1074/jbc.M801371200;
RA   Fu Y., Buryanovskyy L., Zhang Z.;
RT   "Quinone reductase 2 is a catechol quinone reductase.";
RL   J. Biol. Chem. 283:23829-23835(2008).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEX WITH ZINC IONS; FAD
RP   AND IMATINIB.
RX   PubMed=19236722; DOI=10.1186/1472-6807-9-7;
RA   Winger J.A., Hantschel O., Superti-Furga G., Kuriyan J.;
RT   "The structure of the leukemia drug imatinib bound to human quinone
RT   reductase 2 (NQO2).";
RL   BMC Struct. Biol. 9:7-7(2009).
CC   -!- FUNCTION: The enzyme apparently serves as a quinone reductase in
CC       connection with conjugation reactions of hydroquinones involved in
CC       detoxification pathways as well as in biosynthetic processes such
CC       as the vitamin K-dependent gamma-carboxylation of glutamate
CC       residues in prothrombin synthesis. {ECO:0000269|PubMed:18254726}.
CC   -!- CATALYTIC ACTIVITY: 1-(beta-D-ribofuranosyl)-1,4-
CC       dihydronicotinamide + a quinone = 1-(beta-D-
CC       ribofuranosyl)nicotinamide + a quinol.
CC       {ECO:0000269|PubMed:18579530}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC   -!- ENZYME REGULATION: Inhibited by melatonin, resveratrol and 5-
CC       hydroxytryptamine. {ECO:0000269|PubMed:18254726}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=28 uM for NRH {ECO:0000269|PubMed:15078100,
CC         ECO:0000269|PubMed:9367528};
CC         KM=11.6 uM for menadione {ECO:0000269|PubMed:15078100,
CC         ECO:0000269|PubMed:9367528};
CC         KM=252 uM for NADH {ECO:0000269|PubMed:15078100,
CC         ECO:0000269|PubMed:9367528};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15350128,
CC       ECO:0000269|PubMed:16129418, ECO:0000269|PubMed:18254726,
CC       ECO:0000269|PubMed:19236722}.
CC   -!- INTERACTION:
CC       Q9H8Y8:GORASP2; NbExp=3; IntAct=EBI-358466, EBI-739467;
CC       A1L1C6:LRRC7; NbExp=3; IntAct=EBI-358466, EBI-10171988;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- MISCELLANEOUS: Uses dihydronicotinamide riboside (NRH) rather than
CC       NAD(P)H as an electron donor.
CC   -!- SIMILARITY: Belongs to the NAD(P)H dehydrogenase (quinone) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nqo2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02888; AAA60239.1; -; mRNA.
DR   EMBL; AY299456; AAB60642.3; -; Genomic_DNA.
DR   EMBL; AB050248; BAB16974.1; -; Genomic_DNA.
DR   EMBL; AY855291; AAW29945.1; -; Genomic_DNA.
DR   EMBL; AK311746; BAG34689.1; -; mRNA.
DR   EMBL; AL133351; CAI23294.1; -; Genomic_DNA.
DR   EMBL; CH471087; EAW55107.1; -; Genomic_DNA.
DR   EMBL; BC006096; AAH06096.1; -; mRNA.
DR   CCDS; CCDS4481.1; -.
DR   PIR; A32667; A32667.
DR   RefSeq; NP_000895.2; NM_000904.4.
DR   RefSeq; NP_001277150.1; NM_001290221.1.
DR   RefSeq; NP_001305869.1; NM_001318940.1.
DR   UniGene; Hs.533050; -.
DR   PDB; 1QR2; X-ray; 2.10 A; A/B=2-231.
DR   PDB; 1SG0; X-ray; 1.50 A; A/B=2-231.
DR   PDB; 1XI2; X-ray; 1.50 A; A/B=2-231.
DR   PDB; 1ZX1; X-ray; 2.16 A; A/B=1-231.
DR   PDB; 2BZS; X-ray; 2.00 A; A/B=2-231.
DR   PDB; 2QMY; X-ray; 2.50 A; A/B=2-231.
DR   PDB; 2QMZ; X-ray; 2.10 A; A/B=2-231.
DR   PDB; 2QR2; X-ray; 2.45 A; A/B=2-231.
DR   PDB; 2QWX; X-ray; 1.50 A; A/B=1-231.
DR   PDB; 2QX4; X-ray; 1.65 A; A/B=2-231.
DR   PDB; 2QX6; X-ray; 1.75 A; A/B=2-231.
DR   PDB; 2QX8; X-ray; 1.60 A; A/B=2-231.
DR   PDB; 2QX9; X-ray; 2.31 A; A/B=2-231.
DR   PDB; 3FW1; X-ray; 1.75 A; A=1-231.
DR   PDB; 3G5M; X-ray; 1.84 A; A/B=1-231.
DR   PDB; 3GAM; X-ray; 1.98 A; A/B=1-231.
DR   PDB; 3NFR; X-ray; 1.57 A; A/B=2-231.
DR   PDB; 3NHF; X-ray; 2.00 A; A/B=2-231.
DR   PDB; 3NHJ; X-ray; 2.33 A; A/B=2-231.
DR   PDB; 3NHK; X-ray; 1.96 A; A/B=2-231.
DR   PDB; 3NHL; X-ray; 1.57 A; A/B=2-231.
DR   PDB; 3NHP; X-ray; 1.70 A; A/B=2-231.
DR   PDB; 3NHR; X-ray; 1.80 A; A/B=2-231.
DR   PDB; 3NHS; X-ray; 1.78 A; A/B=2-231.
DR   PDB; 3NHU; X-ray; 1.90 A; A/B=2-231.
DR   PDB; 3NHW; X-ray; 1.65 A; A/B=2-231.
DR   PDB; 3NHY; X-ray; 1.90 A; A/B=2-231.
DR   PDB; 3O2N; X-ray; 1.60 A; A/B=2-231.
DR   PDB; 3O73; X-ray; 2.00 A; A/B=1-231.
DR   PDB; 3OVM; X-ray; 2.09 A; A/B=1-231.
DR   PDB; 3OWH; X-ray; 2.28 A; A/B=1-231.
DR   PDB; 3OWX; X-ray; 1.85 A; A/B=1-231.
DR   PDB; 3OX1; X-ray; 2.00 A; A/B=1-231.
DR   PDB; 3OX2; X-ray; 2.41 A; A/B=1-231.
DR   PDB; 3OX3; X-ray; 1.80 A; A/B=1-231.
DR   PDB; 3TE7; X-ray; 1.70 A; A/B=3-230.
DR   PDB; 3TEM; X-ray; 1.45 A; A/B=3-230.
DR   PDB; 3TZB; X-ray; 2.19 A; A/B/C/D=3-230.
DR   PDB; 3UXE; X-ray; 1.50 A; A/B=2-231.
DR   PDB; 3UXH; X-ray; 1.53 A; A/B=2-231.
DR   PDB; 4FGJ; X-ray; 1.35 A; A/B=1-231.
DR   PDB; 4FGK; X-ray; 1.40 A; A/B=1-231.
DR   PDB; 4FGL; X-ray; 1.20 A; A/B/C/D=1-231.
DR   PDB; 4GQI; X-ray; 1.95 A; A/B=2-231.
DR   PDB; 4GR9; X-ray; 2.29 A; A/B=2-231.
DR   PDB; 4QOD; X-ray; 1.35 A; A/B=1-231.
DR   PDB; 4QOE; X-ray; 1.45 A; A/B=1-231.
DR   PDB; 4QOF; X-ray; 1.55 A; A/B=1-231.
DR   PDB; 4QOG; X-ray; 1.40 A; A/B=1-231.
DR   PDB; 4QOH; X-ray; 1.60 A; A/B=1-231.
DR   PDB; 4QOI; X-ray; 1.55 A; A/B=1-231.
DR   PDB; 4QOJ; X-ray; 1.85 A; A/B=1-231.
DR   PDB; 4U7F; X-ray; 1.80 A; A/B=2-231.
DR   PDB; 4U7G; X-ray; 1.96 A; A/B=2-231.
DR   PDB; 4U7H; X-ray; 1.48 A; A/B=2-231.
DR   PDB; 4XDG; X-ray; 1.50 A; A/B=1-231.
DR   PDB; 4XDH; X-ray; 1.90 A; A/B=1-231.
DR   PDB; 4ZVK; X-ray; 1.87 A; A/B=2-231.
DR   PDB; 4ZVL; X-ray; 1.90 A; A/B=2-231.
DR   PDB; 4ZVM; X-ray; 1.97 A; A/B=2-231.
DR   PDB; 4ZVN; X-ray; 1.87 A; A/B=2-231.
DR   PDB; 5BUC; X-ray; 1.87 A; A/B=2-231.
DR   PDB; 5LBT; X-ray; 1.75 A; A/B=1-231.
DR   PDB; 5LBU; X-ray; 1.65 A; A/B=1-231.
DR   PDBsum; 1QR2; -.
DR   PDBsum; 1SG0; -.
DR   PDBsum; 1XI2; -.
DR   PDBsum; 1ZX1; -.
DR   PDBsum; 2BZS; -.
DR   PDBsum; 2QMY; -.
DR   PDBsum; 2QMZ; -.
DR   PDBsum; 2QR2; -.
DR   PDBsum; 2QWX; -.
DR   PDBsum; 2QX4; -.
DR   PDBsum; 2QX6; -.
DR   PDBsum; 2QX8; -.
DR   PDBsum; 2QX9; -.
DR   PDBsum; 3FW1; -.
DR   PDBsum; 3G5M; -.
DR   PDBsum; 3GAM; -.
DR   PDBsum; 3NFR; -.
DR   PDBsum; 3NHF; -.
DR   PDBsum; 3NHJ; -.
DR   PDBsum; 3NHK; -.
DR   PDBsum; 3NHL; -.
DR   PDBsum; 3NHP; -.
DR   PDBsum; 3NHR; -.
DR   PDBsum; 3NHS; -.
DR   PDBsum; 3NHU; -.
DR   PDBsum; 3NHW; -.
DR   PDBsum; 3NHY; -.
DR   PDBsum; 3O2N; -.
DR   PDBsum; 3O73; -.
DR   PDBsum; 3OVM; -.
DR   PDBsum; 3OWH; -.
DR   PDBsum; 3OWX; -.
DR   PDBsum; 3OX1; -.
DR   PDBsum; 3OX2; -.
DR   PDBsum; 3OX3; -.
DR   PDBsum; 3TE7; -.
DR   PDBsum; 3TEM; -.
DR   PDBsum; 3TZB; -.
DR   PDBsum; 3UXE; -.
DR   PDBsum; 3UXH; -.
DR   PDBsum; 4FGJ; -.
DR   PDBsum; 4FGK; -.
DR   PDBsum; 4FGL; -.
DR   PDBsum; 4GQI; -.
DR   PDBsum; 4GR9; -.
DR   PDBsum; 4QOD; -.
DR   PDBsum; 4QOE; -.
DR   PDBsum; 4QOF; -.
DR   PDBsum; 4QOG; -.
DR   PDBsum; 4QOH; -.
DR   PDBsum; 4QOI; -.
DR   PDBsum; 4QOJ; -.
DR   PDBsum; 4U7F; -.
DR   PDBsum; 4U7G; -.
DR   PDBsum; 4U7H; -.
DR   PDBsum; 4XDG; -.
DR   PDBsum; 4XDH; -.
DR   PDBsum; 4ZVK; -.
DR   PDBsum; 4ZVL; -.
DR   PDBsum; 4ZVM; -.
DR   PDBsum; 4ZVN; -.
DR   PDBsum; 5BUC; -.
DR   PDBsum; 5LBT; -.
DR   PDBsum; 5LBU; -.
DR   ProteinModelPortal; P16083; -.
DR   SMR; P16083; -.
DR   BioGrid; 110898; 12.
DR   IntAct; P16083; 12.
DR   MINT; MINT-1133243; -.
DR   STRING; 9606.ENSP00000337773; -.
DR   BindingDB; P16083; -.
DR   ChEMBL; CHEMBL3959; -.
DR   DrugBank; DB04253; CB1954.
DR   DrugBank; DB06695; Dabigatran etexilate.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB08190; N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB01087; Primaquine.
DR   DrugBank; DB02709; Resveratrol.
DR   iPTMnet; P16083; -.
DR   PhosphoSitePlus; P16083; -.
DR   BioMuta; NQO2; -.
DR   DMDM; 317373581; -.
DR   EPD; P16083; -.
DR   MaxQB; P16083; -.
DR   PaxDb; P16083; -.
DR   PeptideAtlas; P16083; -.
DR   PRIDE; P16083; -.
DR   Ensembl; ENST00000338130; ENSP00000337773; ENSG00000124588.
DR   Ensembl; ENST00000380430; ENSP00000369795; ENSG00000124588.
DR   Ensembl; ENST00000380455; ENSP00000369822; ENSG00000124588.
DR   GeneID; 4835; -.
DR   KEGG; hsa:4835; -.
DR   UCSC; uc003mus.3; human.
DR   CTD; 4835; -.
DR   DisGeNET; 4835; -.
DR   GeneCards; NQO2; -.
DR   H-InvDB; HIX0018967; -.
DR   HGNC; HGNC:7856; NQO2.
DR   HPA; HPA021283; -.
DR   HPA; HPA021332; -.
DR   MalaCards; NQO2; -.
DR   MIM; 160998; gene.
DR   neXtProt; NX_P16083; -.
DR   OpenTargets; ENSG00000124588; -.
DR   PharmGKB; PA31745; -.
DR   eggNOG; ENOG410IKWF; Eukaryota.
DR   eggNOG; COG2249; LUCA.
DR   GeneTree; ENSGT00440000033410; -.
DR   HOGENOM; HOG000149970; -.
DR   HOVERGEN; HBG029104; -.
DR   InParanoid; P16083; -.
DR   KO; K08071; -.
DR   OMA; RLQTIWK; -.
DR   OrthoDB; EOG091G183R; -.
DR   PhylomeDB; P16083; -.
DR   TreeFam; TF300296; -.
DR   BRENDA; 1.10.99.2; 2681.
DR   Reactome; R-HSA-211945; Phase 1 - Functionalization of compounds.
DR   SABIO-RK; P16083; -.
DR   EvolutionaryTrace; P16083; -.
DR   GeneWiki; NAD(P)H_dehydrogenase,_quinone_2; -.
DR   GenomeRNAi; 4835; -.
DR   PRO; PR:P16083; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000124588; -.
DR   CleanEx; HS_NQO2; -.
DR   ExpressionAtlas; P16083; baseline and differential.
DR   Genevisible; P16083; HS.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0031404; F:chloride ion binding; IDA:CAFA.
DR   GO; GO:0001512; F:dihydronicotinamide riboside quinone reductase activity; IDA:CAFA.
DR   GO; GO:0009055; F:electron carrier activity; IDA:CAFA.
DR   GO; GO:0071949; F:FAD binding; IDA:CAFA.
DR   GO; GO:1904408; F:melatonin binding; IDA:CAFA.
DR   GO; GO:0016491; F:oxidoreductase activity; IDA:CAFA.
DR   GO; GO:0016661; F:oxidoreductase activity, acting on other nitrogenous compounds as donors; IDA:CAFA.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:CAFA.
DR   GO; GO:1905594; F:resveratrol binding; IDA:CAFA.
DR   GO; GO:0008270; F:zinc ion binding; IDA:CAFA.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:CAFA.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.360; -; 1.
DR   InterPro; IPR003680; Flavodoxin_fold.
DR   InterPro; IPR029039; Flavoprotein-like_dom.
DR   Pfam; PF02525; Flavodoxin_2; 1.
DR   SUPFAM; SSF52218; SSF52218; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; FAD; Flavoprotein;
KW   Metal-binding; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome; Zinc.
FT   CHAIN         1    231       Ribosyldihydronicotinamide dehydrogenase
FT                                [quinone].
FT                                /FTId=PRO_0000071626.
FT   NP_BIND      18     21       FAD. {ECO:0000269|PubMed:18254726,
FT                                ECO:0000269|PubMed:19236722}.
FT   NP_BIND     104    107       FAD. {ECO:0000269|PubMed:18254726,
FT                                ECO:0000269|PubMed:19236722}.
FT   NP_BIND     148    151       FAD. {ECO:0000269|PubMed:18254726,
FT                                ECO:0000269|PubMed:19236722}.
FT   REGION      127    129       Substrate binding.
FT   METAL       174    174       Zinc.
FT   METAL       178    178       Zinc.
FT   METAL       223    223       Zinc.
FT   BINDING      12     12       FAD. {ECO:0000269|PubMed:18254726,
FT                                ECO:0000269|PubMed:19236722}.
FT   BINDING     156    156       FAD. {ECO:0000269|PubMed:18254726,
FT                                ECO:0000269|PubMed:19236722}.
FT   BINDING     194    194       FAD. {ECO:0000269|PubMed:18254726,
FT                                ECO:0000269|PubMed:19236722}.
FT   BINDING     201    201       FAD. {ECO:0000269|PubMed:18254726,
FT                                ECO:0000269|PubMed:19236722}.
FT   MOD_RES      80     80       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     197    197       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VARIANT      16     16       K -> R (in dbSNP:rs28383623).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021399.
FT   VARIANT      29     29       E -> G (in dbSNP:rs17136117).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021400.
FT   VARIANT      47     47       L -> F (in dbSNP:rs1143684).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1691923,
FT                                ECO:0000269|PubMed:8182056,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.4,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_021401.
FT   VARIANT      58     58       G -> D (in dbSNP:rs17300141).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021402.
FT   VARIANT     184    184       V -> A (in dbSNP:rs28383651).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021403.
FT   MUTAGEN     162    162       N->H: Loss of activity toward CB1954, no
FT                                effect toward menadione.
FT                                {ECO:0000269|PubMed:16129418}.
FT   CONFLICT    140    140       G -> C (in Ref. 2; AAB60642).
FT                                {ECO:0000305}.
FT   STRAND        5     10       {ECO:0000244|PDB:4FGL}.
FT   HELIX        18     33       {ECO:0000244|PDB:4FGL}.
FT   STRAND       36     41       {ECO:0000244|PDB:4FGL}.
FT   TURN         42     46       {ECO:0000244|PDB:4FGL}.
FT   HELIX        53     55       {ECO:0000244|PDB:4FGL}.
FT   STRAND       63     65       {ECO:0000244|PDB:4FGL}.
FT   HELIX        68     77       {ECO:0000244|PDB:4FGL}.
FT   HELIX        83     94       {ECO:0000244|PDB:4FGL}.
FT   STRAND       96    103       {ECO:0000244|PDB:4FGL}.
FT   STRAND      105    108       {ECO:0000244|PDB:3O2N}.
FT   HELIX       111    120       {ECO:0000244|PDB:4FGL}.
FT   TURN        123    125       {ECO:0000244|PDB:4FGL}.
FT   STRAND      129    132       {ECO:0000244|PDB:3NHF}.
FT   HELIX       133    135       {ECO:0000244|PDB:4FGL}.
FT   TURN        137    140       {ECO:0000244|PDB:4FGL}.
FT   STRAND      142    148       {ECO:0000244|PDB:4FGL}.
FT   TURN        153    156       {ECO:0000244|PDB:4FGL}.
FT   STRAND      160    162       {ECO:0000244|PDB:1SG0}.
FT   HELIX       165    173       {ECO:0000244|PDB:4FGL}.
FT   HELIX       174    178       {ECO:0000244|PDB:4FGL}.
FT   TURN        179    181       {ECO:0000244|PDB:4FGL}.
FT   STRAND      188    190       {ECO:0000244|PDB:4FGL}.
FT   TURN        193    195       {ECO:0000244|PDB:4FGL}.
FT   HELIX       198    212       {ECO:0000244|PDB:4FGL}.
FT   HELIX       213    217       {ECO:0000244|PDB:4FGL}.
FT   HELIX       225    229       {ECO:0000244|PDB:4FGL}.
SQ   SEQUENCE   231 AA;  25919 MW;  FE1F4D577517B972 CRC64;
     MAGKKVLIVY AHQEPKSFNG SLKNVAVDEL SRQGCTVTVS DLYAMNLEPR ATDKDITGTL
     SNPEVFNYGV ETHEAYKQRS LASDITDEQK KVREADLVIF QFPLYWFSVP AILKGWMDRV
     LCQGFAFDIP GFYDSGLLQG KLALLSVTTG GTAEMYTKTG VNGDSRYFLW PLQHGTLHFC
     GFKVLAPQIS FAPEIASEEE RKGMVAAWSQ RLQTIWKEEP IPCTAHWHFG Q
//
